Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa plus ONCOS-102 in metastatic castration-resistant prostate cancer
2015-004314-15Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Jun 2016
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DCvac, ONCOS-102 and cyclophosphamide in prostate cancer (PCa), sponsored by SOTIO Biotech. Primary endpoint: Safety profile. Started Jun 2016; status: completed.
02
Drugs
DCvacONCOS-102cyclophosphamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-004314-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004314-15.